Altaris Capital Partners Acquires Meridian Medical Technologies from Pfizer
December 30, 2021
Altaris Capital Partners has entered into an agreement to acquire Meridian Medical Technologies from Pfizer. Meridian, a pioneer in emergency response drug-device combination products and auto-injectors with facilities in St. Louis, Missouri and Columbia, Maryland and more than 750 employees, will become an Altaris portfolio company to expand the firm's capabilities in medical countermeasures and emergency response solutions.
- Buyers
- Altaris Capital Partners, LLC
- Targets
- Meridian Medical Technologies
- Sellers
- Pfizer Inc.
- Industry
- Medical Devices
- Location
- Missouri, United States
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
Altaris Combines Kindeva Drug Delivery and Meridian Medical Technologies
December 13, 2022
Medical Devices
Altaris has completed the combination of its portfolio companies Kindeva Drug Delivery and Meridian Medical Technologies into a single, global drug‑device CDMO that will operate under the Kindeva name. The combined company expands capabilities across parenteral, inhalation, transdermal and intradermal delivery formats; Milton Boyer (formerly Meridian CEO) will lead the combined business.
-
Altaris Capital Partners Majority Recapitalizes Minnetronix Medical
February 3, 2021
Medical Devices
Altaris Capital Partners has completed a majority recapitalization of Minnetronix Medical, expanding a relationship in place since 2015 when Altaris was a minority investor. The transaction provides Minnetronix — a Saint Paul, Minnesota-based medical device product development and contract manufacturing partner — with capital and partnership support to accelerate its growth and product strategy.
-
Altaris Acquires Minaris Regenerative Medicine from Resonac
September 23, 2024
Healthcare Services
Altaris, LLC has acquired Minaris Regenerative Medicine from Resonac Corporation, making Minaris a wholly owned portfolio company of Altaris. Minaris is a cell therapy CDMO with six facilities across the United States, Germany and Japan and more than 500 employees; the deal advances Altaris' strategic initiative to build capabilities in cell and gene therapy manufacturing.
-
Altaris Acquires 51% Stake in Solesis from Michelin
June 1, 2021
Medical Devices
Altaris Capital Partners has completed the acquisition of a 51% stake in Solesis from Michelin, with Michelin retaining a 49% ownership interest and partnering with Altaris to build Solesis as an independent company. Solesis, a U.S.-based biomaterials and medical-device components manufacturer operating through The Secant Group, Charter Medical and SanaVita Medical, employs approximately 360 people across production facilities in Pennsylvania and North Carolina.
-
Altaris Capital Partners Acquires Kindeva Drug Delivery from 3M
May 1, 2020
Medical Devices
Altaris Capital Partners has acquired Kindeva Drug Delivery L.P. (formerly 3M Drug Delivery Systems) from 3M Company for $650 million in a corporate carve-out transaction. Monroe Capital provided financing and an equity co-investment to support the deal, and 3M will retain a minority interest alongside Altaris as Kindeva operates independently to pursue growth and capital investments.
-
The Tecan Group Acquires Paramit from Altaris Capital Partners
June 23, 2021
Medical Devices
The Tecan Group has agreed to acquire Paramit Corporation from Altaris Capital Partners for $1.0 billion, with the transaction expected to close in the third quarter. Paramit, headquartered in Morgan Hill, California, is a contract developer and manufacturer of complex electronic medical devices and life science instruments with ~1,000 employees across the U.S. and Malaysia.
Track M&A activity that matters to you
Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.